CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
09 mai 2023 16h15 HE
|
CytomX Therapeutics Inc.
- Continued progress in Phase 1 dose escalation for CX-904 (EGFRxCD3) - - IND enabling activities on track for filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon...
CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023
01 mai 2023 16h01 HE
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
25 avr. 2023 16h05 HE
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
27 mars 2023 16h15 HE
|
CytomX Therapeutics Inc.
- Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b)...
CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023
22 mars 2023 19h23 HE
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
CytomX Therapeutics to Present at Upcoming March Investor Conferences
28 févr. 2023 16h05 HE
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
26 janv. 2023 07h00 HE
|
CytomX Therapeutics Inc.
-Achievement of clinical candidate is the first in the multi-target collaboration and triggers a $5 million milestone payment to CytomX- -CytomX-retained US co-commercialization and economic rights...
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference
17 janv. 2023 16h05 HE
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities
05 janv. 2023 16h05 HE
|
CytomX Therapeutics Inc.
- CX-2029 (CD71 conditionally activated ADC) continued to demonstrate encouraging anti-cancer activity in squamous tumors in the now completed Phase 2 Cohort Expansion Study. AbbVie and CytomX to...
CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
05 janv. 2023 16h05 HE
|
CytomX Therapeutics Inc.
Collaboration will combine Moderna’s mRNA technology with CytomX’s Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million...